IOM On “Omics” Assays: Stricter Controls Are Needed For Development Process
This article was originally published in The Gray Sheet
Executive Summary
The Institute of Medicine recommends a highly controlled, step-wise approach to bringing complex genomic, proteomic and similar assays from basic research to clinical testing. FDA needs to play a central role, IOM stresses in a recent report.